Hers vs MEDVi: Which GLP-1 Provider Is Better?
Short answer: MEDVi scores higher on our rubric, 5.7/10 against 5.3/10. Full reasoning, pricing and the cases where the other one wins are below.
MEDVi beats Hers overall, scoring 5.7/10 vs 5.3/10. Published pricing is not a like-for-like monthly comparison: Hers is $188 first month, then $298/mo; MEDVi is $179 first month, then $299/mo. Choose Hers for women who want a female-focused platform and can budget at least $188 initially and $298/mo ongoing for a $149 medication path. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program.
A side-by-side look at Hers and MEDVi to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
Hers
#26 of 34The women's health arm of Hims & Hers Health (NYSE: HIMS). Hers lists Wegovy pill, Foundayo, and Ozempic pill medication from $149, a Wegovy pen from $199, Zepbound from $299, and compounded options. Wegovy and Foundayo carry FDA approval for weight management. Ozempic is FDA approved for type 2 diabetes and is prescribed off label for weight loss. A required Weight Loss Membership adds $39 in month one and $149/mo thereafter, so the all-in floor for a $149 medication path is $188 initially and $298/mo ongoing; exact product and dose prices vary.
Visit HersMEDVi
#25 of 34MEDVi offers a weekly compounded GLP-1 injection and a daily compounded tablet. The injection is $179 for month one and $299 for refills. Trustpilot is 4.3 out of 5 across 14,680 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.
Visit MEDVi| Feature | Hers | MEDVi |
|---|---|---|
| Why each one | A major women-focused telehealth platform with a direct Novo Nordisk partnership (Wegovy pill from $149 and pen from $199 before required membership) and a Lilly partnership (Zepbound medication from $299) alongside compounded options. | A daily dissolvable GLP-1 tablet and a weekly compounded injection in one program, plus brand-name Wegovy and Zepbound on a $99 membership. |
| Our Score | 5.3/10 | 5.7/10 |
| Headline Price | $188 first month, then $298/mo | $179 first month, then $299/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Women who want a female-focused platform and can budget at least $188 initially and $298/mo ongoing for a $149 medication path | Users who want both oral and injectable compounded options in one telehealth program |
| Watch out for | Pending federal enforcement against the parent company: on July 29, 2026 the FTC, joined by Utah and by California acting through Los Angeles County Counsel, sued Hims & Hers Health, Inc. in the Northern District of California over subscription billing, cancellation friction and sharing consumer health information with advertising platforms. The case status is Pending and these are allegations, not findings (checked 2026-09-03). | FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication |
| Ranking | #26 | #25 |
| Get started | Visit Hers | Visit MEDVi |
Pros & Cons Compared
Hers
Pros
- +Brand-name paths include Wegovy pill, Foundayo, and Ozempic pill medication from $149 and a Wegovy pen from $199. Wegovy and Foundayo carry FDA approval for weight management, Ozempic is approved for type 2 diabetes and is used off label here. With the required membership, a $149 medication path totals $188 initially and $298/mo ongoing
- +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Broader women's health platform, integrates weight loss with hormonal, skin, and wellness services
Cons
- −Pending federal enforcement against the parent company: on July 29, 2026 the FTC, joined by Utah and by California acting through Los Angeles County Counsel, sued Hims & Hers Health, Inc. in the Northern District of California over subscription billing, cancellation friction and sharing consumer health information with advertising platforms. The case status is Pending and these are allegations, not findings (checked 2026-09-03).
- −Every medication figure excludes the required Weight Loss Membership ($39 first month, then $149/mo); exact product and dose prices can increase the total above the $188/$298 floor
- −Support runs at big-platform scale, fine for routine refills, less personal if you want high-touch care
- −Compounded pricing starts at $199/mo with stepped pricing at higher doses, budget for the dose you'll end up on, not the entry dose
- −Zepbound medication starts at $299 before the required membership; that path totals $338 in month one and at least $448/mo ongoing, with exact dose pricing potentially higher
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +The landing page says the program is HSA and FSA eligible and includes dietician visits and care coaching, with a footnote making that subject to insurance and copay eligibility
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179 covers the first month of compounded semaglutide on MEDVi's landing page, including physician review, the personalized plan, medication and free shipping
Cons
- −FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
- −Its third-party records conflict: 4.3 out of 5 across 14,680 Trustpilot reviews with 12 percent of them at one star, against an F and no accreditation at the BBB
- −The $179 semaglutide price covers month one only; the FAQ on MEDVi's own landing page says refills are locked in at $299 a month, making the first year $3,468 rather than $2,148
- −Brand-name Wegovy and Zepbound paths add a $99 membership plus a medication cost the page does not publish, and the same page's hero says "No membership or hidden fees!" directly above those cards; availability is subject to change
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
MEDVi edges out Hers with a score of 5.7/10 vs 5.3/10. Published pricing is not a like-for-like monthly comparison: Hers is $188 first month, then $298/mo; MEDVi is $179 first month, then $299/mo.
Cheapest complete recurring price in our index
Eden Health GLP-1
$99/mo month-to-month, from $34 on a plan · 6.9/10 · Both
Both Hers and MEDVi start above the cheapest complete recurring program we track. Across all 34 providers in our index, the lowest price with affirmative medication, consultation, and shipping inclusion is Eden Health GLP-1 at $99/mo, price checked August 28, 2026. It scores 6.9/10 and is not the highest-scored provider in our full rankings, so this is a cost floor rather than a recommendation. Worth knowing before you decide.
Reviews and pricing sources
Related comparisons
More head-to-head comparisons involving Hers and MEDVi.
Not comparing, just asking? Quick answers to the most-asked GLP-1 questions →
- Compare Hers and Sprout Health$110/mo flat
- Compare Hers and Fridaysfrom $117/mo
- Compare Hers and Eden Health GLP-1$99/mo month-to-month
- Compare MEDVi and Eden Health GLP-1$99/mo month-to-month
- Compare MEDVi and Maximuspublished $79.99/mo; total not verified
- Compare MEDVi and SkinnyRx$99 first month, rises after
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.
Still working out whether either one is above board? We check that separately: is Hers legit and is MEDVi legit, with the verification evidence behind each answer.
Our pick of these two: MEDVi · 5.7/10